CCL2 and atherosclerosis: It has been shown that specific therapies targeting the pro/anti-inflammatory cytokines such as CCL2, TNFα, and IL-6 have suggested slowing in the progression of atherosclerosis in animal models and might improve cardiovascular outcomes in human subjects in large-scale phase III trials.